Generics - Boardroom, Anti-virals

Filter

Current filters:

BoardroomAnti-virals

Popular Filters

1 to 25 of 1683 results

Daiichi Sankyo names Ken Keller as President, US Commercial

Daiichi Sankyo names Ken Keller as President, US Commercial

23-04-2014

Japanese drugmaker Daiichi Sankyo has announced that Ken Keller will join the company as President of…

AmgenBoardroomBusiness FinanceDaiichi SankyoHealth Medical PharmaJapanKen KellerPharmaceuticalPharmaceutical experienceUSA

Lupin appoints Theresa Stevens as Chief Corporate Development Officer

Lupin appoints Theresa Stevens as Chief Corporate Development Officer

23-04-2014

Pharma major Lupin has announced the appointment of Theresa Stevens as Chief Corporate Development Officer…

BoardroomLupinPharmaceuticalUSA

Gilead 1st-qtr 2014 sales nearly double, fuelled by Sovaldi, as net income rockets

23-04-2014

US antivirals major Gilead Sciences posted first-quarter 2014 results after markets closed yesterday,…

Anti-viralsBiotechnologyFinancialGilead SciencesSovaldi

AbbVie files NDA for oral, interferon-free treatment of hepatitis C

22-04-2014

US drugmaker AbbVie has submitted its New Drug Application to the US Food and Drug Administration for…

AbbVieAnti-viralsEnanta PharmaceuticalsFinancialNorth AmericaPharmaceuticalRegulationUSA

Novartis appoints Jeff George as Division Head, Alcon and Richard Francis as Division Head, Sandoz

Novartis appoints Jeff George as Division Head, Alcon and Richard Francis as Division Head, Sandoz

22-04-2014

Swiss drug major Novartis has announced the appointment of Jeff George as Division Head of Alcon and…

AlconBoardroomNorthern EuropeNovartisPharmaceuticalSandoz

e-Therapeutics announces appointment of Steve Medlicott as Finance Director

e-Therapeutics announces appointment of Steve Medlicott as Finance Director

22-04-2014

UK-based drug discovery and development company e-Therapeutics has announced the appointment of Steve…

BoardroomManagementPharmaceutical

Adcock Ingram appoints CEO

Adcock Ingram appoints CEO

22-04-2014

South African drugmaker Adcock Ingram has announced the appointment of Kevin Wakeford (pictured) as Chief…

Adcock IngramBoardroomPharmaceuticalSouth Africa

NHS England agrees funding for Gilead’s hepatitis C drug Sovaldi

18-04-2014

NHS England has approved an £18.7 million ($31.3 million) investment in a new drug for the treatment…

Anti-viralsBiotechnologyFinancialGilead SciencesHealthcareNorthern EuropeSovaldiUK

Jacques Servier, founder and president of Lab Servier, dies aged 92

17-04-2014

French independent drugmaker Laboratories Servier announced that its founder and president, Jacques Servier,…

BoardroomManagementPharmaceuticalServier

Teva and Pfizer settle patent litigation over Celebrex

17-04-2014

Israel-based Teva Pharmaceutical Industries says that its US subsidiary has settled a law suit with US…

Anti-Arthritics/RheumaticsCelebrexGenericsNorth AmericaPatentsPfizerTeva Pharmaceutical IndustriesUSA

Astellas US promotes Jeffrey Bloss to SVP of medical affairs for the Americas

Astellas US promotes Jeffrey Bloss to SVP of medical affairs for the Americas

16-04-2014

The US subsidiary of Japanese drug major Astellas Pharma announced that Jeffrey Bloss has been promoted…

Astellas PharmaBoardroomManagementPharmaceuticalUSA

Prosonix and Mylan in deal for Flixotide and Flovent generics

15-04-2014

Prosonix, a UK-based company which is developing a portfolio of inhaled “Respiratory Medicines by Design,”…

FloventGenericsGlaxoSmithKlineGlobalLicensingMylan LaboratoriesProsonixRespiratory and Pulmonary

FTC imposes conditions on Akorn’s proposed buy of Hi-Tech Pharmacal

15-04-2014

In order to consummate the proposed $640 million acquisition of Hi-Tech Pharmacal by fellow USA-based…

ActavisAkornGenericsHi-Tech PharmacalMergers & AcquisitionsNorth AmericaUSA

Depomed settlements with two Gralise ANDA filers

15-04-2014

US specialty drugmaker Depomed has entered into settlement agreements with two of the three defendants…

DepomedGenericsGraliseIncepta PharmaceuticalsLegalNeurologicalNorth AmericaPatentsUSAZydus Cadila

AbbVie achieves response rate of 96% in Phase III trials of hepatitis C treatment

AbbVie achieves response rate of 96% in Phase III trials of hepatitis C treatment

14-04-2014

US drugmaker AbbVie has revealed promising new results from its hepatitis C development program at the…

AbbVieAnti-viralsPharmaceuticalResearchUSA

Indian govt plans to support a competitive pharma sector, especially for SMEs

Indian govt plans to support a competitive pharma sector, especially for SMEs

14-04-2014

In a bid to strengthen the existing infrastructure facilities and to enable the Indian pharmaceutical…

Asia-PacificGenericsIndiaMarkets & MarketingPoliticsProduction

Impressive data for once-daily sofosbuvir and ledipasvir treatment of HCV genotype 1

12-04-2014

Strong results from three Phase III clinical trials (ION-1, ION-2 and ION-3) evaluating the investigational…

Anti-viralsBiotechnologyGilead SciencesledipasvirResearchsofosbuvirSovaldi

1 to 25 of 1683 results

Back to top